抗NMDAR脑炎合并胶质或神经元表面抗体的临床意义
该研究在646例连续确诊的抗NMDAR脑炎患者队列(C1)及200例系统复筛患者队列(C2)中,用大鼠脑免疫染色和细胞法检测合并胶质抗体或神经元表面抗体的情况。结果显示合并抗体者占4%(C1)至7.5%(C2),其中胶质抗体占71%、神经元表面抗体占29%;合并神经元表面抗体者实质性恢复比例低于合并胶质抗体者(5/10[50%] vs 17/19[89%],p=0.03)。
要点
- 抗NMDAR脑炎患者中4%–7.5%合并胶质或神经元表面抗体
- 合并抗体多在脑脊液检出,部分血清检测阴性
- 合并神经元表面抗体者恢复较差,需关注预后
核心结论
- 抗NMDAR脑炎患者中4%–7.5%存在合并胶质抗体或神经元表面抗体,部分抗体可带来额外临床影像特征并可能影响预后。
研究设计与样本
- 研究纳入C1队列646例连续确诊的抗NMDAR脑炎患者及C2队列200例系统复筛患者,采用大鼠脑免疫染色和细胞法检测抗体。
主要发现
- 42例检出合并抗体(C1占4%,C2占7.5%),其中30例(71%)为胶质抗体、12例(29%)为神经元表面抗体。
- 胶质抗体包括MOG(57%)、GFAP(33%)、AQP4(10%);神经元表面抗体包括AMPAR(50%)、GABAaR(42%)、GABAbR(8%)。
- 41例中39例(95%)合并抗体在脑脊液检出,17例(41%)血清检测不到合并抗体。
- 合并神经元表面抗体者实质性恢复比例低于合并胶质抗体者(5/10[50%] vs 17/19[89%],p=0.03)。
关键数值与推荐
- 合并抗体总比例为4%(C1)至7.5%(C2);胶质抗体占71%,神经元表面抗体占29%。
- MOG-Ab占胶质抗体的57%,GFAP-Ab占33%,AQP4-Ab占10%。
- AMPAR-Ab占神经元表面抗体的50%,GABAaR-Ab占42%,GABAbR-Ab占8%。
- 41例中39例(95%)合并抗体在脑脊液检出,17例(41%)血清检测不到。
临床怎么用
- 对抗NMDAR脑炎患者应警惕合并胶质或神经元表面抗体,必要时行脑脊液抗体检测。
- MOG-Ab、AQP4-Ab及神经元表面抗体可提示额外临床影像特征,应结合病史、影像和大鼠脑免疫染色综合判断。
- 合并神经元表面抗体者预后可能较差,临床随访中需加强评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the frequency and significance of concurrent glial (glial-Ab) or neuronal-surface (NS-Ab) antibodies in patients with anti-NMDA receptor (NMDAR) encephalitis. METHODS: Patients were identified during initial routine screening of a cohort (C1) of 646 patients consecutively diagnosed with anti-NMDAR encephalitis and another cohort (C2) of 200 patients systematically rescreened. Antibodies were determined with rat brain immunostaining and cell-based assays. RESULTS: Concurrent antibodies were identified in 42 patients (4% from C1 and 7.5% from C2): 30 (71%) with glial-Ab and 12 (29%) with NS-Ab. Glial-Ab included myelin oligodendrocyte glycoprotein (MOG) (57%), glial fibrillary acidic protein (GFAP) (33%), and aquaporin 4 (AQP4) (10%). NS-Ab included AMPA receptor (AMPAR) (50%), GABAa receptor (GABAaR) (42%), and GABAb receptor (8%). In 39 (95%) of 41 patients, concurrent antibodies were detected in CSF, and in 17 (41%), concurrent antibodies were undetectable in serum. On routine clinical-immunologic studies, the presence of MOG-Ab and AQP4-Ab was suggested by previous episodes of encephalitis or demyelinating disorders (8, 27%), current clinical-radiologic features (e.g., optic neuritis, white matter changes), or standard rat brain immunohistochemistry (e.g., AQP4 reactivity). GFAP-Ab did not associate with distinct clinical-radiologic features. NS-Ab were suggested by MRI findings (e.g., medial temporal lobe changes [AMPAR-Ab], or multifocal cortico-subcortical abnormalities [GABAaR-Ab]), uncommon comorbid conditions (e.g., recent herpesvirus encephalitis), atypical tumors (e.g., breast cancer, neuroblastoma), or rat brain immunostaining. Patients with NS-Ab were less likely to have substantial recovery than those with glial-Ab (5 of 10 [50%] vs 17 of 19 [89%], p = 0.03). CONCLUSIONS: Between 4% and 7.5% of patients with anti-NMDAR encephalitis have concurrent glial-Ab or NS-Ab. Some of these antibodies (MOG-Ab, AQP4-Ab, NS-Ab) confer additional clinical-radiologic features and may influence prognosis.
引用
- Martinez-Hernandez E, Guasp M, García-Serra A, et al. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Neurology. 2020. PMID: 32161029. doi:10.1212/WNL.0000000000009239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。